Biotech Values

[gofishmarko]

Dynavax says Hep B vaccine meets study goal

(A good PR for all the TLR drug cos.)

Tue Nov 28, 2006 4:24 PM ET

CHICAGO, Nov 28 (Reuters) - Dynavax Technologies Corp. <DVAX.O> on Tuesday said its investigational vaccine for Hepatitis B met its goal of providing better protection against the virus compared to a rival vaccine, pushing shares up 31 percent in after-hours trade.

The company said its late-stage trial found its vaccine, called Heplisav, provided protection against the virus in 100 percent of subjects, compared with 73.1 percent of subjects receiving another vaccine called Engerix-B, made by GlaxoSmithKline Plc <GSK.L>.

Dynavax said the results of the 400-person trial were statistically significant.

http://tinyurl.com/w4ff6

More detail in Yahoo PR :

http://tinyurl.com/y5llny